Takaya Ikeda

ORCID

Publication Activity (10 Years)

Years Active: 2018-2020
Publications (10 Years): 4

Top Venues

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. Thoracic cancer 11 (7) (2020)
Shinnosuke Takemoto, Yoichi Nakamura, Hiroshi Gyoutoku, Hiroaki Senju, Daiki Ogawara, Takaya Ikeda, Hiroyuki Yamaguchi, Takeshi Kitazaki, Hirofumi Nakano, Katsumi Nakatomi, Shinya Tomari, Shuntaro Sato, Seiji Nagashima, Minoru Fukuda, Hiroshi Mukae
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. Thoracic cancer 10 (3) (2019)
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, Hiroshi Soda, Katsumi Nakatomi, Nanae Sugasaki, Akitoshi Kinoshita, Seiji Nagashima, Takaya Ikeda, Yoichi Nakamura, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Hiroshi Mukae
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thoracic cancer 10 (9) (2019)
Takaya Ikeda, Hiroyuki Yamaguchi, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyoutoku, Hiroaki Senju, Noriho Sakamoto, Satoshi Iwanaga, Yutaka Kuwatsuka, Minoru Fukuda, Hiroshi Mukae
Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. Thoracic cancer 9 (11) (2018)

Takaya Ikeda.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Takaya Ikeda